# Amador Bioscience

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/amador-bioscience

- Industry: Biotechnology
- Headquarters: Pleasanton, US
- Website: www.amadorbioscience.com
- Total disclosed funding: $60M
- Latest round: Series B (Dec 30, 2021)
- Investors on record: 5

## About

Amador Bioscience, Inc. focuses on integrating clinical pharmacology, bioanalysis, and clinical research, providing essential solutions for the pharmaceutical and biotechnology industries to streamline drug development processes.Founded in 2018 and headquartered in Pleasanton, California, Amador Bioscience, Inc. specializes in clinical pharmacology and bioanalytical services. The firm completed its Series B funding round in December 2021, successfully raising USD 60 mn led by MSA Capital, with involvement from Sequoia Capital, GL Ventures, and Co-Win Ventures. The company has engaged in a total of 2 deals since inception, aiming to strengthen its clinical capabilities and expand its service offerings globally. The founding team includes Rong Zeng and Tony Lee, with Bing Wang currently serving as CEO.Amador Bioscience specializes in integrating clinical pharmacology, bioanalysis, and clinical research, providing comprehensive solutions tailored for the pharmaceutical and biotechnology sectors. The company's core product offerings encompass a range of services designed to support drug development processes, including bioanalytical testing, pharmacokinetic studies, and clinical trial management. These services aim to enhance the efficiency and effectiveness of drug development for clients focused on bringing new therapeutics to market. The firm addresses critical challenges faced by its diverse clientele, including pharmaceutical companies, biotech firms, and academic institutions. Amador Bioscience's expertise ensures compliance with regulatory standards and optimizes research outcomes across markets in North America, Europe, and Asia, with significant operations in California, Maryland, Michigan, Belgium, Hangzhou, Shanghai, and Beijing.Amador Bioscience generates revenue through its suite of specialized services aimed at the life sciences sector, operating primarily on a business-to-business model. The company engages in various transaction structures, including service contracts with pharmaceutical and biotech firms, structured as project-based agreements or ongoing partnerships. This transactional framework allows clients to leverage Amador Bioscience's capabilities for specific phases of their product development lifecycle. Pricing plans are determined based on the complexity and scope of the projects undertaken, ensuring tailored solutions that meet unique research needs. The company’s flagship services are designed to help clients achieve their clinical development goals effectively, enabling a streamlined pathway to market for new therapeutics.In December 2021, Amador Bioscience, Inc. raised USD 60 mn in Series B funding to enhance its clinical pharmacology business, expand global bioanalytical services, and further improve early clinical development capabilities. The company aims to introduce new products designed to enhance its service offerings in the coming years. Additionally, there are plans to expand into new markets, specifically targeting growth opportunities in Europe and Asia by 2024. The recent funding will be crucial in supporting these initiatives, driving innovation and operational enhancements to better serve clients in the pharmaceutical and biotechnology sectors.

## Funding rounds

- Series B, Dec 30, 2021, $60M — Hong Shan, MSA Capital, Co-Win Ventures, GL Ventures
- Series B, Sep 28, 2021 — Hong Shan, MSA Capital, Co-Win Ventures, CMB International Capital Limited, GL Ventures

## Investors

- Hong Shan — Series B
- MSA Capital (https://capitalatlas.ai/funds/msa-capital) — Series B
- Co-Win Ventures (https://capitalatlas.ai/funds/co-win-ventures) — Series B
- CMB International Capital Limited — Series B
- GL Ventures (https://capitalatlas.ai/funds/gl-ventures) — Series B